In this episode of Denatured, youll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics
In the stomach, GLP-1 slows gastric emptying, meaning food stays in the stomach longer before moving into the small intestine
Nh vy, Glutathione v L-Glutathione u l nhng hot cht chng Oxy ha rt tuyt vi
Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders
But in terms of thyroid testing, [00:36:00] TSH, which your brain says to your thyroid, how does it respond
One of the biggest studies to draw attention looked at adults with overweight or obesity and established cardiovascular disease, but without diabetes